1.Ray Dorsey E Elbaz A Nichols E et al.

Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.

Lancet Neurol. 17: 939-9532.

Parkinson's disease.

Lancet. 386: 896-9123.McFarthing K Buff S Rafaloff G Dominey T Wyse RK Stott SRW

Parkinson's disease drug therapies in the clinical trial pipeline: 2020.

J Parkinsons Dis. 10: 757-7744.Barker RA Björklund A Gash DM et al.

GDNF and Parkinson's disease: where next? a summary from a recent workshop.

J Parkinsons Dis. 10: 875-8915.Espay AJ Kalia LV Gan-Or Z et al.

Disease modification and biomarker development in Parkinson disease: revision or reconstruction?.

Neurology. 94: 481-4946.Nguyen M Wong YC Ysselstein D Severino A Krainc D

Synaptic, mitochondrial, and lysosomal dysfunction in Parkinson's disease.

Trends Neurosci. 42: 140-1497.

Modulation of the microbiome in Parkinson's disease: diet, drug, stool transplant, and beyond.

Neurotherapeutics. 17: 1406-14178.Bezard E Yue Z Kirik D Spillantini MG

Animal models of Parkinson's disease: limits and relevance to neuroprotection studies.

Mov Disord. 28: 61-709.

Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Br J Pharmacol. 164: 1357-139110.

The MitoPark Mouse-an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons.

Parkinsonism Relat Disord. 15: S185-S18811.Volpicelli-Daley LA Luk KC Patel TP et al.

Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death.

Neuron. 72: 57-7112.

Modeling Lewy pathology propagation in Parkinson's disease.

Parkinsonism Relat Disord. 20: S85-S8713.Burbulla LF Song P Mazzulli JR et al.

Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease.

Science. 357: 1255-126114.Carling PJ Mortiboys H Green C et al.

Deep phenotyping of peripheral tissue facilitates mechanistic disease stratification in sporadic Parkinson's disease.

Prog Neurobiol. 18710177215.Mortiboys H Aasly J Bandmann O

Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease.

Brain. 136: 3038-305016.

Midbrain organoids: a new tool to investigate Parkinson's disease.

Front Cell Dev Biol. 8: 35917.Naoi M Maruyama W Shamoto-Nagai M

Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.

J Neural Transm. 127: 131-14718.Rascol O Fitzer-Attas CJ Hauser R et al.

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.

Lancet Neurol. 10: 415-42319.Mitchell T Archer DB Chu WT et al.

Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in Parkinsonism.

Hum Brain Mapp. 40: 5094-510720.Mollenhauer B Caspell-Garcia CJ Coffey CS et al.

Longitudinal analyses of cerebrospinal fluid α-synuclein in prodromal and early Parkinson's disease.

Mov Disord. 34: 1354-136421.Eberling JL Dave KD Frasier MA

α-synuclein imaging: a critical need for Parkinson's disease research.

J Parkinsons Dis. 3: 565-56722.Alcalay RN Levy OA Waters CC et al.

Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.

Brain. 138: 2648-265823.Rango M Dossi G Squarcina L Bonifati C

Brain mitochondrial impairment in early-onset Parkinson's disease with or without PINK1 mutation.

Mov Disord. 35: 504-50724.Arora S Baig F Lo C et al.

Smartphone motor testing to distinguish idiopathic REM sleep behavior disorder, controls, and PD.

Neurology. 91: e1528-e153825.Espay AJ Bonato P Nahab FB et al.

Technology in Parkinson's disease: challenges and opportunities.

Mov Disord. 31: 1272-128226.Fahn S Oakes D Shoulson I et al.

Levodopa and the progression of Parkinson's disease.

N Engl J Med. 351: 2498-250827.Verschuur CVM Suwijn SR Boel JA et al.

Randomized delayed-start trial of levodopa in Parkinson's disease.

N Engl J Med. 380: 315-32428.Thibault L Rascol O Corvol JC et al.

New perspectives on study designs for evaluating neuroprotection in Parkinson's disease.

Mov Disord. 32: 1365-137029.Elm JJ Hauser R Tilley BC et al.

Design innovations and baseline findings in a long-term Parkinson's trial: The National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's disease Long-term Study-1.

Mov Disord. 27: 1513-152130.Kieburtz K Katz R McGarry A Olanow CW

A new approach to the development of disease-modifying therapies for PD; fighting another pandemic.

Mov Disord. 36: 59-6331.

The threshold theory for Parkinson's disease.

Trends Neurosci. 40: 4-1432.Chartier-Harlin MC Kachergus J Roumier C et al.

α-synuclein locus duplication as a cause of familial Parkinson's disease.

Lancet. 364: 1167-116933.Paumier KL Luk KC Manfredsson FP et al.

Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.

Neurobiol Dis. 82: 185-19934.Mao X Ou MT Karuppagounder SS et al.

Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3.

Science. 353aah337435.Kordower JH Chu Y Hauser RA Freeman TB Olanow CW

Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease.

Nat Med. 14: 504-50636.Braak H Rüb U Gai WP Del Tredici K

Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen.

J Neural Transm. 110: 517-53637.Chen Z Yang Y Yang X et al.

Immune effects of optimized DNA vaccine and protective effects in a MPTP model of Parkinson's disease.

Neurol Sci. 34: 1559-157038.Sanchez-Guajardo V Annibali A Jensen PH Romero-Ramos M

α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model.

J Neuropathol Exp Neurol. 72: 624-64539.Schneeberger A Tierney L Mandler M

Active immunization therapies for Parkinson's disease and multiple system atrophy.

Mov Disord. 31: 214-22440.Bergström AL Kallunki P Fog K

Development of passive immunotherapies for synucleinopathies.

Mov Disord. 31: 203-21341.Schenk DB Koller M Ness DK et al.

First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers.

Mov Disord. 32: 211-21842.Mittal S Bjørnevik K Im DS et al.

β2-adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease.

Science. 357: 891-89843.Searles Nielsen S Gross A Camacho-Soto A Willis AW Racette BA

β2-adrenoreceptor medications and risk of Parkinson disease.

Ann Neurol. 84: 683-69344.Alexander GM Schwartzman RJ Nukes TA Grothusen JR Hooker MD

β 2-adrenergic agonist as adjunct therapy to levodopa in Parkinson's disease.

Neurology. 44: 1511-151345.Uc EY Lambert CP Harik SI Rodnitzky RL Evans WJ

Albuterol improves response to levodopa and increases skeletal muscle mass in patients with fluctuating Parkinson disease.

Clin Neuropharmacol. 26: 207-21246.

Activating autophagy as a therapeutic strategy for Parkinson's disease.

CNS Drugs. 32: 1-1147.Hantschel O Superti-Furga G

Regulation of the c-Abl and Bcr-Abl tyrosine kinases.

Nat Rev Mol Cell Biol. 5: 33-4448.Hebron ML Lonskaya I Moussa CEH

Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models.

Hum Mol Genet. 22: 3315-332849.Pagan F Hebron M Valadez EH et al.

Nilotinib effects in Parkinson's disease and dementia with lewy bodies.

J Parkinsons Dis. 6: 503-51750.Pagan FL Hebron ML Wilmarth B et al.

Pharmacokinetics and pharmacodynamics of a single dose nilotinib in individuals with Parkinson's disease.

Pharmacol Res Perspect. 7e0047051.Simuni T Kostrzebski M Fiske B et al.

Abstract book of the 5th World Parkinson Congress, Kyoto, Japan, June 4–7, 2019.

J Parkinsons Dis. 9: 1-27852.Orenstein SJ Kuo S-H Tasset I et al.

Interplay of LRRK2 with chaperone-mediated autophagy.

Nat Neurosci. 16: 394-40653.Nalls MA Blauwendraat C Vallerga CL et al.

Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies.

Lancet Neurol. 18: 1091-110254.Cresto N Gardier C Gubinelli F et al.

The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.

Eur J Neurosci. 49: 339-36355.Lee BD Shin JH VanKampen J et al.

Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.

Nat Med. 16: 998-100056.Manzoni C Mamais A Dihanich S et al.

Inhibition of LRRK2 kinase activity stimulates macroautophagy.

Biochim Biophys Acta. 1833: 2900-291057.Di Maio R Hoffman EK Rocha EM et al.

LRRK2 activation in idiopathic Parkinson's disease.

Sci Transl Med. 10eaar542958.Zhao HT John N Delic V et al.

LRRK2 antisense oligonucleotides ameliorate α-synuclein inclusion formation in a Parkinson's disease mouse model.

Mol Ther Nucleic Acids. 8: 508-51959.Korecka JA Thomas R Hinrich AJ et al.

Splice-switching antisense oligonucleotides reduce LRRK2 kinase activity in human LRRK2 transgenic mice.

Mol Ther Nucleic Acids. 21: 623-63560.Sidransky E Nalls MA Aasly JO et al.

Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

N Engl J Med. 361: 1651-166161.Do J McKinney C Sharma P Sidransky E

Glucocerebrosidase and its relevance to Parkinson disease.

Mol Neurodegener. 14: 3662.McNeill A Magalhaes J Shen C et al.

Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.

Brain. 137: 1481-149563.Mullin S Smith L Lee K et al.

Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial.

JAMA Neurol. 77: 427-43464.Aflaki E Borger DK Moaven N et al.

A new glucocerebrosidase chaperone reduces α-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and parkinsonism.

J Neurosci. 36: 7441-745265.Rocha EM Smith GA Park E et al.

Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.

Neurobiol Dis. 82: 495-50366.Sardi SP Viel C Clarke J et al.

Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models.

Proc Natl Acad Sci USA. 114: 2699-270467.Gan-Or Z Liong C Alcalay RN

GBA-associated Parkinson's disease and other synucleinopathies.

Curr Neurol Neurosci Rep. 18: 4468.

Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER.

69.Chan CS Guzman JN Ilijic E et al.

‘Rejuvenation’ protects neurons in mouse models of Parkinson's disease.

Nature. 447: 1081-108670.Ilijic E Guzman JN Surmeier DJ

The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease.

Neurobiol Dis. 43: 364-37171.Becker C Jick SS Meier CR

Use of antihypertensives and the risk of Parkinson disease.

Neurology. 70: 1438-144472.Parkinson Study Group STEADY-PD III Investigators

Isradipine versus placebo in early Parkinson disease: a randomized trial.

Ann Intern Med. 172: 591-59873.Dexter DT Wells FR Agid F et al.

Increased nigral iron content in postmortem parkinsonian brain.

Lancet. 2: 1219-122074.Langkammer C Pirpamer L Seiler S et al.

Quantitative susceptibility mapping in Parkinson's disease.

PLoS One. 11e016246075.Martin-Bastida A Ward RJ Newbould R et al.

Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease.

Sci Rep. 7139876.International Parkinson's Disease Genomics Consortium

A two-stage meta-analysis identifies several new loci for Parkinson's disease.

PLoS Genet. 7e100214277.

Glia: initiators and progressors of pathology in Parkinson's disease.

Mov Disord. 26: 6-1778.Imamura K Hishikawa N Sawada M Nagatsu T Yoshida M Hashizume Y

Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains.

Acta Neuropathol. 106: 518-52679.Gendelman HE Zhang Y Santamaria P et al.

Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial.

NPJ Parkinsons Dis. 3: 1080.Gellhaar S Sunnemark D Eriksson H Olson L Galter D

Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson's and Alzheimer's disease.

Cell Tissue Res. 369: 445-45481.Posener JA Hauser RA Stieber M et al.

Safety, tolerability, and pharmacodynamics of AZD3241, a myeloperoxidase inhibitor, in Parkinson's disease.

Mov Disord. 29: S259-S26082.Jucaite A Svenningsson P Rinne JO et al.

Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease.

Brain. 138: 2687-270083.Codolo G Plotegher N Pozzobon T et al.

Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies.

PLoS One. 8e5537584.Qiao C Zhang Q Jiang Q et al.

Inhibition of the hepatic Nlrp3 protects dopaminergic neurons via attenuating systemic inflammation in a MPTP/p mouse model of Parkinson's disease.

J Neuroinflammation. 15: 19385.Gordon R Albornoz EA Christie DC et al.

Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice.

Sci Transl Med. 10eaah406686.

Simvastatin as a potential disease-modifying therapy for patients with Parkinson's disease: rationale for clinical trial, and current progress.

J Parkinsons Dis. 7: 545-56887.Carroll CB Stevens K Jones B et al.

Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): results of a double-blind, randomised, placebo-controlled futility study. MDS Virtual Congress 2020. Late Breaking Abstracts; Online.

88.Gao HM Zhang F Zhou H Kam W Wilson B Hong JS

Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.

Environ Health Perspect. 119: 807-81489.Williams-Gray CH Wijeyekoon R Yarnall AJ et al.

Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD).

Mov Disord. 31: 995-100390.

Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology.

Nat Rev Rheumatol. 16: 167-17891.Greenland JC Cutting E Kadyan S Bond S Chhabra A Williams-Gray CH

Azathioprine immunosuppression and disease modification in Parkinson's disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol.

BMJ Open. 10e04052792.Velseboer DC de Bie RMA Wieske L et al.

Development and external validation of a prognostic model in newly diagnosed Parkinson disease.

Neurology. 86: 986-99393.Exner N Lutz AK Haass C Winklhofer KF

Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

EMBO J. 31: 3038-306294.Pinto M Nissanka N Peralta S Brambilla R Diaz F Moraes CT

Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation.

Mol Neurodegener. 11: 2595.Simuni T Kieburtz K Tilley B et al.

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.

Lancet Neurol. 14: 795-80396.Schwarzschild MA Ascherio A Beal MF et al.

Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.

JAMA Neurol. 71: 141-15097.Gong L Zhang QL Zhang N et al.

Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3β signaling pathway.

J Neurochem. 123: 876-88598.Beal MF Oakes D Shoulson I et al.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

JAMA Neurol. 71: 543-55299.Prasuhn J Brüggemann N Hessler N et al.

An omics-based strategy using coenzyme Q10 in patients with Parkinson's disease: concept evaluation in a double-blind randomized placebo-controlled parallel group trial.

Neurol Res Pract. 1: 31100.Mortiboys H Furmston R Bronstad G Aasly J Elliott C Bandmann O

UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S) carriers and in vivo.

Neurology. 85: 846-852101.Keene CD Rodrigues CMP Eich T Chhabra MS Steer CJ Low WC

Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease.

Proc Natl Acad Sci USA. 99: 10671-10676102.Sathe AG Tuite P Chen C et al.

Pharmacokinetics, safety, and tolerability of orally administered ursodeoxycholic acid in patients with Parkinson's disease-a pilot study.

J Clin Pharmacol. 60: 744-750103.

Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.

Sci Rep. 810722104.Zhang L Zhang L Li L Hölscher C

Semaglutide is neuroprotective and reduces α-synuclein levels in the chronic MPTP mouse model of Parkinson's disease.

J Parkinsons Dis. 9: 157-171105.Aviles-Olmos I Dickson J Kefalopoulou Z et al.

Exenatide and the treatment of patients with Parkinson's disease.

J Clin Invest. 123: 2730-2736106.Aviles-Olmos I Dickson J Kefalopoulou Z et al.

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.

J Parkinsons Dis. 4: 337-344107.Athauda D Maclagan K Skene SS et al.

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Lancet. 390: 1664-1675108.Athauda D Gulyani S Karnati HK et al.

Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the Exenatide-PD trial.

JAMA Neurol. 76: 420-429